AstraZeneca completes agreement with LEO Pharma


This announcement contains inside information

16 August 2016 07:00

ASTRAZENECA COMPLETES GLOBAL LICENCING
AGREEMENT WITH LEO PHARMA FOR TRALOKINUMAB

AstraZeneca today announced that it has completed the licensing
agreement (https://www.astrazeneca.com/media-centre/press
-releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin
-diseases-01072016.html) with LEO Pharma A/S (LEO Pharma), a specialist in
dermatology care, for the global licence to tralokinumab in skin diseases.
Tralokinumab is an IL-13 monoclonal antibody that has completed a Phase IIb
trial for the treatment of patients with atopic dermatitis, an inflammatory skin
disease resulting in itchy, red, swollen and cracked skin.

Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of
$115 million for the exclusive, global rights to tralokinumab in atopic
dermatitis and any future additional dermatology indications. As AstraZeneca
will retain a significant ongoing interest in tralokinumab, the upfront payment,
along with all future commercial milestone and royalty payments, will be
reported as Externalisation Revenue in the Company's financial statements.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas - Respiratory and
Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company
is also active in inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media
Enquiries
Neil           UK/Global                              +44 203 749 5637
Burrows
Vanessa        UK/Global                              +44 203 749 5736
Rhodes
Karen          UK/Global                              +44 203 749 5634
Birmingham
Rob            UK/Global                              +44 203 749 5821
Skelding
Jacob Lund     Sweden                                 +46 8 553 260 20
Michele        US                                     +1 302 885 2677
Meixell
Investor
Relations
UK
Thomas Kudsk                                          +44 203 749 5712
Larsen
Craig Marks    Finance, Fixed Income, M&A             +44 7881 615 764
Nick Stone     Respiratory & Autoimmunity             +44 203 749 5716
Henry          Oncology                               +44 203 749 5797
Wheeler
Christer       Infection & Neuroscience               +44 203 749 5711
Gruvris
US
Lindsey        Cardiovascular & Metabolic   Diseases  +1 240 543 7970
Trickett
Mitchell        Oncology                              +1 240 477 3771
Chan
Toll free                                             +1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-

Pièces jointes

08160430.pdf